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Abstract To look over the distribution of the mutations in
a large series from Adana province, Southern Turkey, and
determine the genotype-phenotype correlation of the fre-
quent mutations. Among the 2500 individuals with mild or
moderate anemia, microcytosis, and normal iron levels that
were referred to our Genetic Diagnosis Center, a population
consisting of 539 individuals were included in the study and
tested for alpha-thalassemia mutations by using reverse dot
blot hybridization technique. Twelve different mutations
were detected in 539 patients. Among the 12 different
mutations found, the most frequent mutations were the –a3.7
(63.3 %), –MED (11.7 %), –20.5 (10.7 %), a2IVS1(-5nt)
(3.9 %), and a2polyA-2 (3.5 %). The most frequent geno-
types were –a3.7/aa (35.8 %), –a3.7/-a3.7(18.9 %), –20.5/aa
(11.5 %), and –MED/aa (10.4 %), respectively. There were
statistically significant differences in hematological findings
between –a3.7/–a3.7 and –MED/aa, even though both have
two mutated genes in the genotype. Our results show that
alpha-thalassemia mutations are highly heterogeneous as
well as deletional and –a3.7 single gene deletion is particu-
larly prevalent at Adana province in agreement to other
studies from Turkey.
Keywords Alpha-thalassemia  Mutation 
Phenotype-genotype correlation
Introduction
Microcytic hypochromic anemia is a common condition of
alpha-thalassemia (OMIM 141800), which is the most
common single-gene disorder in Turkey as it is worldwide
[1]. Adana is located in the southern part of Turkey and
takes place in the eastern Mediterranean coast of the
thalassemic belt. Alpha-thalassemia is a genetic defect
extremely frequent worldwide, especially in Southeast
Asian, Mediterranean, and Middle Eastern populations, and
is characterized by the decrease or complete suppression of
a-globin polypeptide chains, resulting from over 128 dif-
ferent deletions or point mutations of the alpha globin
genes [2, 3].
Alpha-globin genes (a1 and a2) are located at the short
arm of chromosome 16 (16p13.3). There are four func-
tional a genes, termed as aa/aa, in normal individuals [4].
The clinical signs are caused mostly by the deletion of one
(–a/) or both (–/) cis-linked a-globin genes and less fre-
quently by non-deletional mutations (aTa or aaT) [4, 5].
Alpha-thalassemia is an autosomal recessive disorder
characterized by microcytic hypochromic anemia and a
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clinical phenotype varying from almost-asymptomatic to
lethal hemolytic anemia [6]. Alpha-thalassemia is often
initially suspected on the basis of a routine full blood count.
The key components of the full blood count include
hemoglobin, red blood cell (RBC) number, mean corpus-
cular volume (MCV/fl), mean corpuscular hemoglobin
(MCH/pg), and red cell distribution width. All affected
individuals have a variable degree of anemia, reduced
MCH, reduced MCV, and a normal or slightly reduced level
of the minor HbA2 at electrophoresis. A wide range of
clinical phenotypes is produced depending on the number of
alpha-thalassemia alleles [7]. Carriers of a single mutant a-
globin gene are clinically silent and show little to no
hemoglobin (Hb) abnormalities. Those with two affected
genes have mild microcytic hypochromic anemia with
normal Hb A2 levels. Mutations in three a-globin genes lead
to Hemoglobin H (HbH) disease due to a marked imbalance
in the globin chain synthesis ratio. Homozygosity for alpha-
thalassemia is the cause of HbH disease, characterized by
the development of hemolytic anemia of a variable degree,
and the lethal Hb Barts hydrops fetalis syndrome [8].
Although it is accepted that the clinical phenotypes vary
according to the number of mutated genes, this study was
planned for the prediction of phenotypes that can vary not
only according to the number of mutated genes, but also to
the character of the mutation.
Materials and Methods
Study Design
The study was approved by the Ethical committee and
written informed consent was obtained from the subjects.
The study was in compliance with the Helsinki declaration.
Among the 2500 individuals with mild or moderate anemia,
microcytosis, and normal iron levels that were referred to
Adana Numune Training and Research Hospital Genetic
Diagnosis Center for detection of thalassemia mutations, a
population consisting of 539 individuals were included in the
study. We investigated patients who were referred to our
center for probable iron deficiency anemia and beta thalas-
semia, at first step. Hence we evaluated patients’ blood
serum iron, total iron binding capacity, ferritin, transferring
saturation index, peripheral blood smear and hemoglobin
electrophoresis. Patients with beta thalassemia and iron
deficiency anemia were excluded from the study. We
detected small group patients who are hematologically
compatible with iron deficiency anemia as well as thalasse-
mia. These criteria were low hemoglobin, low MCV and
MCHC, but normal or higher RBC level according to the age.
Hematological parameters were analyzed using (on) the
CD 3700 automatic cell counter (Abbott, Santa Clara, CA).
The high performance liquid chromatography was per-
formed to detect the carriers of hemoglobin variants. The
Primus Ultra2 Resolution method was used according to
manufacturers’ instructions (Primus Corporation, Kansas
City, USA). The age, sex, spleen status, transfusion history,
and hematological parameters, including total hemoglobin,
RBC, HbA2, HbF, MCV, and MCH, were recorded for
each patient. Skeletal deformity was absent in all subjects.
After obtaining written informed consent, 2 ml of blood
was collected in EDTA from each patient.
Molecular Analysis
Blood samples were collected and DNA was extracted by
the salting out procedure [9]. Alpha globin mutations were
analyzed using multiplex-PCR and reverse-hybridization
assay according to the instructions provided by the manu-
facturer (Alpha-globin StripAssay; ViennaLab Diagnostics,
Vienna, Austria), covering the following 21 mutations: two
single gene deletions (-3.7, -4.2), five double gene dele-
tions [–MED, –SEA, –THAI, –FIL, –20.5 kb], anti-a-3.7-kb
a triplication, two point mutations on the a1 gene [codon 14
(TGG [ TAG); codon 59 (GGC [ GAC) (Hb Adana)], and
11 mutations on the a2 gene [initiation codon ATG [ ACG;
codon 19 (GCG [ GC-), IVS-I(-5 nt) (-TGAGG); codon
59 (GGC [ GAC); codon 125 (CTG [ CCG) (Hb Quong
Sze); Hb Constant Spring (HbCS) a142, Term ? Gln,
TAA [ CAA; Hb Icaria, a142, Term ? Lys, TAA [ AAA;
Hb Pakse´, Term ? Tyr, TAA [ TAT, Hb Koya Dora,
a142, Term ? Ser, TAA [ TCA; polyadenylation signal
(polyA) AATAAA [ AATAAG (polyA1); polyA2
AATAAA [ AATGAA] [5].
Table 1 Number and frequency of mutated a-globin alleles in
patients from Adana, Turkey
Mutation Number
of alleles
Frequency
(%)
-3.7 450 63.3
–MED 83 11.7
–20.5 76 10.7
IVS1(-5nt) 28 3.9
a2PolyA-2 25 3.5
anti-3.7 19 2.7
a2 Poly A-1 10 1.4
-4.2 7 1
Hb Icaria 5 0.7
a1 cd 59 [G [ A](Hb Adana) 4 0.6
a2 cd 142 [T [ C](Constant Spring) 2 0.3
–SEA 2 0.3
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Statistical Analysis
Statistical analysis was carried out by custom scripts
implemented in R (http://www.r-project.org) and an inde-
pendent sample t test was used for comparison of hema-
tological parameters. Genotypic and allelic frequencies
were also calculated.
Results
A total of 539 patients met the eligibility criteria for the
study. Of the 539 patients (37.1 % male and 62.9 %
female), the mean age was 27.7 ± 17.6 (range 1–82) years.
The frequencies of a-globin allele and genotypes and the
corresponding mean hematological values for all 539 patients
were listed in Table 1 and Table 2. A total of 12 different a-
globin variants were found, the most common 5 alpha-thalas-
semia mutations were -3,7, which comprises 63.3 % of the
total mutated alleles, followed by –MED (11.7 %), -20.5
(10.7 %), a2 IVS1 (-5nt) (3.9 %), and a2 PolyA-2 (3.5 %).
These five mutations make up 93.1 % of total mutations.
Hemoglobin Constant Spring (HbCS) was detected in two
patients for the first time in Turkey. Furthermore, –SEA dele-
tion, the most frequent alpha-thalassemia mutation in China and
Southeast Asia, was detected in only two patients (Table 1).
In this study we report that 29 alpha-thalassemia geno-
types have been found in the Adana region of Turkey and
that the most common genotypes have prevalence of
35.8 % (–a3.7/aa), 18.9 % (–a3.7/–a3.7), and 11.5 % (–20.5/
aa), respectively (Table 2). Hematological parameters
were analyzed in relation to the genotype and the MCV
value was found to be the lowest in the –MED/–a3.7 and the
highest in the –a3.7/aa genotype. The MCH and the MCHC
levels were also consistent with this finding. In summary,
hematological indices were further reduced as the number
of functional genes decreased (Table 2).
When the hematological values of the non-deletional
mutations were compared to deletional mutations of
genotypes that had one gene defect, there was no statisti-
cally significant difference (Table 3).
We also compared the hematological findings of patients
who had the most common three genotypes with two gene
deletions (Group 1: –a3.7/–a3.7; Group 2: –MED/aa; Group
3: –20.5/aa). We identified a significant difference between
RBC and MCV indices, although both groups have two
deleted genes in their genotype (Table 4).
Discussion
The thalassemias and abnormal hemoglobins constitute a
group of the most common hereditary blood disorders in
the world caused by quantitative or structural defects in
hemoglobin synthesis [2, 3]. In our country, a broad range
of mutations have been observed, probably because of
Turkey’s location amongst three continents and the influ-
ence of different cultures over the course of history. The
Turkish population is a mixture of different ethnic groups;
hence, the frequency and distribution of a-globin mutations
in various regions of the country need to be clarified.
Mutations in a-globin genes are characterized by the
absence or reduced expression of a-globin chains. Gene
deletions including –a17.4, –a26.5, –a20.5, a2-5nt, –a3.7, and
–a4.2, mutations including a2-Poly A1, a2-Poly A2 and a1 cd
59 G [ A point mutation and aaaanti-3.7 gene triplication
have been reported in several studies from our country and
the frequency of –a3.7 deletion has been reported to be
rather high as in other populations of Mediterranean basin
[4, 5]. The most common genotypes in Iraq were –a3.7/aa,
–MED/aa and –a3.7/–a3.7 which were detected in 65.1 % of
the study group [6]. In the present study, 12 different
alleles and 29 genotypes were identified. –a3.7 mutation
was the most common with an allele frequency of 63.3 %.
Oner et al. [10] found the allele frequency of –a3.7 deletion
as 28 % in 25 patients with alpha-thalassemia. In a study
on patients with alpha-thalassemia from Cukurova region
by Curuk et al., it was shown that there was –a3.7 mutation
in 59.3 % of patients and allele frequency was 29.6 % [11].
Guvenc et al. detected –a3.7 deletion in 181 of 450 alleles
from 225 patients with alpha-thalassemia and allele fre-
quency was reported as 40.66 % [12]. In a study by Sutcu
et al. [13] in which distribution of alpha-thalassemia
mutations was investigated at Isparta province, –a3.7 allele
frequency was 5.55 %. –a3.7 gene deletion is the most
frequently seen mutations in West Asia countries including
Iran (40–93 %), United Arab Emirates (28.4 %), Saudi
Arabia (64 %), Oman (58.3 %), Tunisia (22.5 %), Jordan
(43 %), and Israel (51 %) [14–20]. Similarly, a3.7 gene
deletion is the most frequently seen mutation in Europe
with the allele frequencies of 58.2 % in Holland, 46.94 %
Table 3 The comparison of heterogeneous deletions with heteroge-
neous non-deletional mutations for samples with single affected gene
p Value Mean non-
deletions ± SD
(min–max)a
Mean deletions ± SD
(min–max)b
Hb 0.842 12.2 ± 2.2 (9.1–14.8) 12.2 ± 1.4 (5.7–18)
RBC 0.372 5.2 ± 3.4 (3.7–6.4) 4.9 ± 0.6 (2.2–12.8)
MCV 0.525 74.9 ± 7.5 (55.4–88.8) 73.9 ± 7.1 (49.4–89.9)
MCH 0.744 24.9 ± 3.2 (17.3–29.1) 24.8 ± 2.6 (13.9–33.6)
MCHC 0.647 33.3 ± 1.8 (31.1–35.5) 33.4 ± 1.1 (27.6–44.4)
a a2IVS1(-5nt)/aa, a2PolyA2/aa, a2Polya -1/aa; aHb Adana/aa;
aHbConstantSpring/aa; aHb Icaria/aa
b –a3.7/aa, –a4.2/aa
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in Sicily and 52.41 % in Spain [21]. This is also true for
Malaysia (45.9 %), Brazil (10.7 %) and North Thailand
(58.3 %) [22]. These results show that –a3.7 gene deletion
is prevalent worldwide including our country and indicate
that our results are in agreement with literature.
The –a3.7 deletion is the most frequent a-globin muta-
tion, while frequencies of the aaaanti-3.7 triplication are
only sporadically known [23]. The aaaanti-3.7 triplication
was found lower than –a3.7 deletion in our study, similar to
other studies worldwide.
–MED double-gene deletion, the second most frequently
detected mutation, was found with a frequency of 11.7 %
in our study. This mutation was the second most commonly
seen mutation in the studies by Curuk et al. and Guvenc
et al., whereas the third most commonly seen mutation in
the study by Oner et al. with allele frequencies of 9.55,
14.06 and 20 %, respectively [10–12]. In the study by
Sutcu et al. [13] it was reported as 27.77 %. The most
frequently seen deletional mutation in Cyprus Turks with a
frequency of 40 % was –MED double-gene deletion [24].
Hemoglobin Constant Spring (HbCS), usually seen in
Asian populations, is characterized by an elongated a chain
with additional 31 amino acid residues, caused by a point
mutation in the termination codon of the a2-globin gene
(HBA2 c.427T [ C) [25, 26]. HbCS was detected in two
patients for the first time in Turkey. –SEA deletion, the
most frequent alpha-thalassemia mutation in China and
Southeast Asia, was detected in only two patients [27, 28].
The key to successful detection of the thalassemias is
the initial hematological parameters. Hematological
parameters of patients with alpha-thalassemia were com-
pared with those of patients with iron deficiency anemia
and a- thalassemia. We know that RDW level is increased
more in iron deficiency than thalassemia while RBC is
increased in thalassemia [29, 30]. As it is known that the
hematological parameters can manifest differences
according to the type of the mutation, we revealed signif-
icant alterations for different types of mutations. Although
two functional genes were found in each group, there was a
statistically significant difference between –a3.7/–a3.7,
–MED/aa, and –20.5/aa, while there were no difference
between the latter two. The levels of transcription of the
two alpha globin genes differ; the a2 gene produces two to
three times more a-globin than the a1 gene and our results
support this information [29]. We did not determine any
statistically significant difference between the hematolog-
ical values of the non-deletional mutations as compared to
deletional mutations of genotypes that had one gene defect.
However, the non-deletion alpha-thalassemia mutations
should have more severe effects on a-globin gene expres-
sion [31].
The limitation of this study is not confirming the results
with functional studies. On the other hand, many patients
with anemia suspected of alpha thalassemia were excluded
from this study because none of these mutations were
found in these patients with the reverse dot blot method.
Our results show that alpha-thalassemia mutations are
highly heterogeneous as well as deletional and –a3.7 single
gene deletion is particularly prevalent at Adana province in
agreement to other studies from Turkey. These results may
be useful for genetic counseling and diagnosis. The present
study is also important in terms of the potential contribu-
tion to development of national database of hemoglobin-
opathy gene mutations.
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